MarketPulse

DCCR

6 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Soleno Therapeutics Faces Securities Lawsuit Over Undisclosed Drug Safety Risks

$SLNO investors urged to join class action over undisclosed DCCR safety concerns; May 5, 2026 deadline.
SLNOsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Claimsfiler

Soleno Therapeutics Faces Securities Lawsuit Over Undisclosed DCCR Safety Risks

Soleno Therapeutics ($SLNO) faces class action lawsuit alleging executives failed to disclose material safety concerns with its lead drug DCCR, with lead plaintiff deadline set for May 5, 2026.
SLNOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kessler Topaz Meltzer & Check, Llp

SLNO Stock Plummets 26% on Safety Concerns: Class Action Lawsuit Filed Against Soleno Therapeutics

Soleno Therapeutics faces securities fraud lawsuit over alleged safety misstatements in DCCR clinical trial. Stock fell 26% following August short-seller report.
SLNOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

Soleno Therapeutics Faces Securities Fraud Lawsuit Over Undisclosed Safety Issues

Law firm Kahn Swick & Foti alleges Soleno Therapeutics failed to disclose material safety concerns with its flagship DCCR product, with lead plaintiff applications due May 5, 2026.
SLNOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Soleno Therapeutics Faces Class Action Over Undisclosed Safety Risks in DCCR Drug

Rosen Law Firm files securities class action against $SLNO for alleged misstatements regarding safety concerns with DCCR drug candidate for Prader-Willi syndrome treatment.
SLNOsecurities class actionlead plaintiff
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

Soleno Therapeutics Faces Securities Lawsuit Over Alleged DCCR Safety Disclosure Failures

Class action lawsuit filed against Soleno Therapeutics for allegedly failing to disclose material safety concerns about its DCCR product. Investors can apply as lead plaintiff by May 5, 2026.
SLNOsecurities fraudclass action lawsuit